ANABV — AnaptysBio Share News
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
Brief: AnaptysBio Q4 Net Income USD -42.211 Million
AnaptysBio Inc expected to post a loss of $1.63 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Booking Holdings, Eli Lilly, Markel Group
Brief: AnaptysBio Q3 net income USD -37.308 million
U.S. STOCKS ON THE MOVE-Illumina, AnaptysBio, Royal Caribbean Group
Anaptys soars as skin disease treatment succeeds in late-stage study
AnaptysBio's skin disease drug meets main goal in late-stage study (updated)
Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab (Il-36R)
AnaptysBio's skin disease drug meets main goal in late-stage study
Brief: Anaptysbio Announces Appointment Of John Orwin As Chairman Of The Board Of Directors
AnaptysBio Inc reports results for the quarter ended in June - Earnings Summary
AnaptysBio Inc expected to post a loss of $1.70 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Anaptysbio, Booking Holdings, Ulta Beauty
TD Cowen initiates coverage on AnaptysBio with 'outperform'; shares up
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
AnaptysBio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Anaptysbio Reports First Quarter 2023 Financial Results
AnaptysBio Inc expected to post a loss of $1.05 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Bank of America, JP Morgan, Morgan Stanley